ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PROK
ZURA (29) TECX (30) AUTL (21) TRXB (48) ⌘ Pro Terminal →

ProKidney Corp. (Class A) (PROK) — RQD Stock Rating Cockpit

$1.12 -13.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

ProKidney Corp. (Class A) (PROK) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $391.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PROK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PROK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ProKidney Corp. (Class A) (NASDAQ: PROK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.12 (-13.51% 1D, market cap $391.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PROK ranks #595 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PROK compare to ZURA and TECX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PROK carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $389.2M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, PROK leads on earnings multiple (N/A) while PROK leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PROK?
▼

Per PROK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850270), ProKidney Corp. (Class A) generated $462.0M in revenue (-10.2% YoY), -$69.0M in net income, and -$135.3M in free cash flow against $335.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.09 (-2.62%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE PROK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY PROK SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 40.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$1.57-8.3% Next Q
Q2 (-2Q)
40
Grade D$1.44+4.9% Next Q
Q3 (-1Q)
38
Grade E$1.51-25.8% Next Q
Current
35
Grade D-$1.12-8.5% Hist 90D α
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PROK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PROK currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.18) forces dealer call-delta covering toward $3.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PROK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
40.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.12H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PROK

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like PROK
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROK)

  • ✓Walkthrough of PROK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PROK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.43%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.47H $1.47L $1.12C $1.12VOL 1.73M
RES: $1.96SUP: $1.09SMA50: $1.66SMA200: $1.81
$2.48$2.11$1.74$1.37$1.01RES $1.96SUP $1.09$1.122026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PROK Butterfly Map → + Track PROK →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PROK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PROK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PROK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROK)

Health Care Rank #595 of 1016 ⚔️ ZURA vs PROK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PROK vs. ZURA, TECX, AUTL, TRXB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ProKidney Corp. (Class A) (PROK) ranks #595 by composite RQD confidence (35/100, grade D-) and #477 by equity capitalization ($391.6M). Within this direct 5-issuer industry benchmark cohort, PROK leads on earnings valuation at N/A trailing P/E, while PROK leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with PROK at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PROK ACTIVE
ProKidney Corp. (Class A)
D- 35/100 — — -35.0% -13.51% $391.6M Benchmark Subject
ZURA
Zura Bio Limited (Class A)
E 29/100 — — -35.0% -2.47% $389.2M /zura-vs-prok →
TECX
Tectonic Therapeutic Inc.
E 30/100 — — -35.0% -4.04% $386.7M /tecx-vs-prok →
AUTL
Autolus Therapeutics plc
E 21/100 — -27.8% -35.0% -6.58% $404.6M /autl-vs-prok →
TRXB
TRex Bio Inc.
D 48/100 — — — -0.73% $377.1M /trxb-vs-prok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850270

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProKidney Corp. (Class A) (PROK) reported GAAP revenue of $462.0M (-10.2% vs. FY2024 revenue of $514.3M , and +8.9% cumulative change since FY2023) , GAAP net income of -$69.0M, operating cash flow of -$120.1M, and free cash flow of -$135.3M (+13.2% YoY). On the balance sheet, PROK closed FY2025 with $335.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $462.0M -$69.0M -$120.1M -$135.3M $335.6M —
FY2024 (FY) 2024-12-31 $514.3M -$61.2M -$126.4M -$155.9M $441.1M —
FY2023 (FY) 2023-12-31 $424.3M -$35.5M -$90.1M -$90.1M — —

3. PROK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ProKidney Corp. (Class A) (NASDAQ: PROK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.12 (-13.51% 1D, market cap $391.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PROK ranks #595 in composite RQD confidence.

How does PROK compare to ZURA and TECX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PROK carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $389.2M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, PROK leads on earnings multiple (N/A) while PROK leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PROK?

Per PROK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850270), ProKidney Corp. (Class A) generated $462.0M in revenue (-10.2% YoY), -$69.0M in net income, and -$135.3M in free cash flow against $335.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PROK trading relative to its 50-day, 200-day, and 52-week technical levels?

PROK last traded at $1.12 (-13.51% on volume of 7,298,278 shares), positioning the stock -32.53% below its 50-day simple moving average ($1.66) and -38.12% below its 200-day simple moving average ($1.81). Across its 52-week range of $1.29 to $3.10, PROK sits at the 0.0% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.26).

Direct Sub-Reports: PROK RQD Cockpit PROK 12M Forecast PROK Earnings & Move PROK Dividends & DRIP PROK Insiders & 13F PROK Whale Options PROK Profit Sankey PROK News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PROK — ProKidney Corp. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ProKidney Corp. (Class A) (PROK) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.12 (-13.51% 1D, market capitalization $391.6M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (Class A) (PROK) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile reports a market capitalization of $0.4B. — for how the company makes money or who its customers are.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ProKidney Corp. (Class A) (PROK) reported $462.0M in annual revenue (up from $514.3M in FY2024, -10.2% YoY) and -$69.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($424.3M revenue, -$35.5M net income) through FY2025, PROK scaled operating cash flow to -$120.1M and free cash flow to -$135.3M, backed by $335.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.29 – $3.10 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply_chain field is NONE and butterfly_links and proprietary_signals are empty. Upstream and downstream dependencies are — Sector correlation data is — beyond the Health Care sector classification.

  • Key Question #1: Can PROK sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $462.0M and free cash flow of -$135.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PROK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PROK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ProKidney Corp. (Class A) (PROK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PROK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PROK Bull vs. Bear Conversation Board — What's Your Call at $1.12?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PROK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PROK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.62 (+24.6%)
📌 Pinned Debate

Balance-sheet pillar is not distressed, with Altman Z 2.5 and Debt/Equity 0.5 alongside reported cash of $108.5M.

Don't sleep on PROK's setup in Health Care. Balance-sheet pillar is not distressed, with Altman Z 2.5 and Debt/Equity 0.5 alongside reported cash of $108.5M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (35/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.00 (-23.1%)
Spot @ $1.30

Reported revenue is $0.0M across all listed periods while FCF was -$135.3M in FY 2025 and ROIC is -35%.

I respect the product at ProKidney Corp. (Class A), but the stock at $1.30 is a different story. Reported revenue is $0.0M across all listed periods while FCF was -$135.3M in FY 2025 and ROIC is -35%.. FCF yield is 0.0% and RQD sits at 35/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%